ES2156255T3 - Procedimiento para preparar antagonistas del receptor de fibrinogeno. - Google Patents

Procedimiento para preparar antagonistas del receptor de fibrinogeno.

Info

Publication number
ES2156255T3
ES2156255T3 ES96202049T ES96202049T ES2156255T3 ES 2156255 T3 ES2156255 T3 ES 2156255T3 ES 96202049 T ES96202049 T ES 96202049T ES 96202049 T ES96202049 T ES 96202049T ES 2156255 T3 ES2156255 T3 ES 2156255T3
Authority
ES
Spain
Prior art keywords
procedure
fibrinogen
antagonists
receiver
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96202049T
Other languages
English (en)
Inventor
John Y L Chung
David L Hughes
Dalian Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2156255T3 publication Critical patent/ES2156255T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA INVENCION PROPORCIONA UN COMPUESTO DE FORMULA: O UNA SAL DEL MISMO Y UN PROCEDIMIENTO PARA SU PREPARACION.
ES96202049T 1992-02-28 1993-02-20 Procedimiento para preparar antagonistas del receptor de fibrinogeno. Expired - Lifetime ES2156255T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/843,658 US5206373A (en) 1992-02-28 1992-02-28 Process for preparing fibrinogen receptor antagonists

Publications (1)

Publication Number Publication Date
ES2156255T3 true ES2156255T3 (es) 2001-06-16

Family

ID=25290632

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96202049T Expired - Lifetime ES2156255T3 (es) 1992-02-28 1993-02-20 Procedimiento para preparar antagonistas del receptor de fibrinogeno.
ES93200486T Expired - Lifetime ES2105069T3 (es) 1992-02-28 1993-02-20 Procedimiento para preparar antagonistas del receptor de fibrinogeno.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES93200486T Expired - Lifetime ES2105069T3 (es) 1992-02-28 1993-02-20 Procedimiento para preparar antagonistas del receptor de fibrinogeno.

Country Status (25)

Country Link
US (1) US5206373A (es)
EP (2) EP0558139B1 (es)
JP (1) JP2674679B2 (es)
KR (1) KR100187779B1 (es)
CN (1) CN1050832C (es)
AR (1) AR247878A1 (es)
AT (1) ATE156118T1 (es)
AU (2) AU3732293A (es)
CA (1) CA2090509C (es)
CZ (1) CZ283485B6 (es)
DE (1) DE69312528T2 (es)
DK (1) DK0558139T3 (es)
ES (2) ES2156255T3 (es)
FI (1) FI106023B (es)
GR (2) GR3024965T3 (es)
HU (2) HU226957B1 (es)
LV (1) LV12824B (es)
MX (1) MX9301045A (es)
NZ (1) NZ249751A (es)
RO (1) RO116016B1 (es)
RU (2) RU2114105C1 (es)
SK (1) SK281250B6 (es)
TW (1) TW229206B (es)
WO (1) WO1993016995A1 (es)
YU (1) YU49077B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264813B1 (it) * 1993-07-28 1996-10-10 Oxon Italia Spa Procedimento per la preparazione di alcansolfonammidi
US5780480A (en) * 1996-02-28 1998-07-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5980951A (en) * 1996-04-10 1999-11-09 Merck & Co., Inc. Oral coated active drugs
EP0925063A4 (en) 1996-07-01 2000-12-27 Lilly Co Eli Blood-glucose-lowering and lipid-lowering compounds
GB9812088D0 (en) * 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
CN1330636C (zh) * 2005-09-26 2007-08-08 鲁南制药集团股份有限公司 盐酸替罗非班中间体的合成方法
CN102452975A (zh) * 2010-11-01 2012-05-16 天津康鸿医药科技发展有限公司 盐酸替罗非班中间体合成方法
CN104447509B (zh) * 2013-09-18 2016-08-24 嘉实（湖南）医药科技有限公司 一种盐酸替罗非班的制备工艺
CN108440393A (zh) * 2018-03-20 2018-08-24 成都倍特药业有限公司 替罗非班物料杂质、杂质制备及物料中杂质检测方法
CN109608387A (zh) * 2019-01-02 2019-04-12 海门慧聚药业有限公司 盐酸替罗非班的制备
CN111100066B (zh) * 2019-11-29 2021-07-30 石药集团恩必普药业有限公司 一种盐酸替罗非班中间体及盐酸替罗非班的制备方法
CN112816282B (zh) * 2020-12-29 2022-04-12 江苏慧聚药业股份有限公司 一种盐酸替罗非班的有关物质及其制备和检测方法
CN115181058B (zh) * 2021-04-01 2024-06-11 武汉武药科技有限公司 组合物及其质量控制方法
CN114315697A (zh) * 2021-12-20 2022-04-12 河北国龙制药有限公司 一种盐酸替罗非班的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB756713A (en) * 1953-07-06 1956-09-05 Ciba Ltd Substituted piperidines and process of making them
GB772516A (en) * 1953-12-22 1957-04-17 Ciba Ltd Piperidines and process of making same
GB939019A (en) * 1959-01-19 1963-10-09 Aspro Nicholas Ltd Diphenyl methane derivatives and methods for the preparation thereof
IT1062206B (it) * 1974-02-01 1983-09-20 Rotta Research Lab S P A A S Derivati della tirosina attivi sulla muscolatura liscia
DE2809377A1 (de) * 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
LV12824B (en) 2002-09-20
AU657199B2 (en) 1995-03-02
SK281250B6 (sk) 2001-01-18
FI106023B (fi) 2000-11-15
DE69312528D1 (de) 1997-09-04
AR247878A1 (es) 1995-04-28
CN1050832C (zh) 2000-03-29
AU3383693A (en) 1993-09-02
GR3024965T3 (en) 1998-01-30
DK0558139T3 (da) 1997-09-01
AU3732293A (en) 1993-09-13
HU9600658D0 (en) 1996-05-28
RU2114105C1 (ru) 1998-06-27
YU49077B (sh) 2003-08-29
LV12824A (en) 2002-05-20
NZ249751A (en) 1996-06-25
CA2090509C (en) 1997-02-25
JPH069557A (ja) 1994-01-18
DE69312528T2 (de) 1998-02-19
CA2090509A1 (en) 1993-08-29
FI943933A (fi) 1994-10-04
SK102294A3 (en) 1995-04-12
YU13193A (sh) 1997-07-31
EP0738714B1 (en) 2001-05-02
EP0738714A3 (en) 1996-11-20
EP0738714A2 (en) 1996-10-23
CZ283485B6 (cs) 1998-04-15
KR950700252A (ko) 1995-01-16
ES2105069T3 (es) 1997-10-16
WO1993016995A1 (en) 1993-09-02
MX9301045A (es) 1993-09-01
GR3035827T3 (en) 2001-08-31
HU9402467D0 (en) 1994-10-28
RO116016B1 (ro) 2000-09-29
CN1076441A (zh) 1993-09-22
ATE156118T1 (de) 1997-08-15
EP0558139A1 (en) 1993-09-01
CZ203394A3 (en) 1995-10-18
FI943933A0 (fi) 1994-08-26
EP0558139B1 (en) 1997-07-30
KR100187779B1 (ko) 1999-06-01
TW229206B (es) 1994-09-01
HUT70537A (en) 1995-10-30
HU226957B1 (en) 2010-03-29
US5206373A (en) 1993-04-27
HU217959B (hu) 2000-05-28
JP2674679B2 (ja) 1997-11-12
RU94040166A (ru) 1996-07-10
RU2097377C1 (ru) 1997-11-27

Similar Documents

Publication Publication Date Title
ES2156255T3 (es) Procedimiento para preparar antagonistas del receptor de fibrinogeno.
ES2059290T1 (es) Aril-haloalquilpirazoles sustituidos herbicidas.
KR930703311A (ko) 물질 p의 길항제인 n-알킬 퀴누클리디늄염
GB9514473D0 (en) Chemical compounds
MX9204111A (es) Triazoles substituidos y procedimiento para su obtencion.
BG97409A (en) Herbicidal substituted arylalkylsulphonyl pyrazoles
BG99863A (en) Antagonists of fibrogenous receptor
AR002157A1 (es) Uso de una dosis inmunizante eficaz de esporozoitos o merozoitos de eimeria vivos, o una mezcla de los mismos
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
NO911122D0 (no) Fremgangsmaate for fremstilling av antihyperkolesterolemiske midler.
JO1704B1 (en) New potent compounds
ES2152328T3 (es) Antagonistas del receptor del fibrinogeno.
EA199800230A1 (ru) Тетрагидрохинолины в качестве антагонистов nmda (n-метил-d-аспарагиновой кислоты)
IS4367A (is) CCK eða gastrín temprandi 5-heterósýklísk-1,5-bensódíazepín
AR002245A1 (es) Antagonistas del receptor de adhesion, procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos parapreparar medicamentos.
MX9803634A (es) Difenileteroxazolinas y su empleo como agentes pesticidas.
YU48399B (sh) Jedinjenja 7-acil-3-(supstituisanih karbamoiloksi) cefema i postupak za njihovo dobijanje
ES2114115T3 (es) Procedimiento y nuevos productos intermedios para la obtencion de triazolinonas.
MX9302878A (es) Procedimiento para la preparacion de un diaminodiol substituido.
MX9300035A (es) Tratamiento de movimiento involuntarios con agonistas de receptores de 5ht1a.
ATE248163T1 (de) Neuartige, pharmazeutisch aktive verbindung
GR1001309B (el) Μεθοδος παρασκευης παραγωγου ενωσεως της διχλωροανιλινης.
FI934468A (fi) Bensenborsyraderivat, foerfarande foer deras framstaellning och deras anvaendning som sytes mellanprodukter
ES8701182A1 (es) Un procedimiento para preparar sal monosodica del acido 7-d-mandelamido-3-(1-sulfometiltetrazol-5-il)tiometil-3-cefem-4-carboxilico
ES2063014T3 (es) Derivados de 2-oxa-isocefemo, composiciones que los contienen y procedimientos de preparacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 738714

Country of ref document: ES